Nate Pile started in the Electrical Engineering/Computer Science program at U.C. Berkeley, but wound up with a degree in Mathematics from Cal. While in school, he was lucky enough to meet and spend time working for legendary biotech analyst Jim McCamant, a life-changing experience that inspired Pile to eventually launch his own newsletter, Nate’s Notes, in 1995.
Articles by Nate Pile
The top five holdings of this ETF are: AdvisorShares Sage Core Reserves ETF (HOLD), 35.79% of assets; Fidelity Instl Govt 657 C, 4.83%; PTC Inc (PTC), 4.42%; MasTec Inc (MTZ), 3.73%; and MSCI Inc (MSCI), 3.68 %.
More than 214,000 shares have been purchased by the insiders of this biotech in the past three months. The shares are trading a very price, reflecting the company’s turnaround status.
This fund is an opportunity to diversify your biotech holdings. It has a current dividend yield of 8.87%, paid quarterly.
This healthcare fund just paid a distribution of $0.36 per share on March 31. The previous payment was in November, 2016, for $.040.
TheStreet.com also likes this biotech, recently noting, “A clear take out of the February highs, just above $117.65, could provide the spark needed to send the biotech stock sharply higher.”
From Nate’s Notes
Despite providing some very encouraging guidance at the JP Morgan Conference this...
This previous Top Pick is trying to overcome a dismal 2016. The company received a $1 million milestone payment from Receptor Life Sciences, Inc. (RLS) at the end of the year, and analysts are forecasting 80%+ growth in 2017 for the company. However, aware...
This tech company posted EPS of $0.44 last quarter, handily beating analysts’ estimates of $0.28 per share. Nine analysts have raised their forecasts for the company in the past 30 days.
Cirrus Logic (CRUS)From Nate’s Notes
Cirrus Logic (CRUS) has also joined the parade of that...